Vivani Medical Receives FDA Clearance for Trial of Type-2 Diabetes Mini-Implant
By Karen Roman
Vivani Medical, Inc. (Nasdaq: VANI) said the FDA allowed the beginning of a phase 1 for the clinical trial of NPM-119, its long-term mini-implant for type-2 diabetes treatment.
Vivani is also advancing in the development of NPM-115 and NPM-139, both treatments for chronic weight management, it said.
“Today marks a significant milestone for Vivani as we transition to a clinical-stage company with a promising drug candidate that has the potential to address medication non-adherence, which affects approximately 50% of patients with type 2 diabetes,” said Adam Mendelsohn, Ph.D., Vivani’s President and CEO. “The results of the study will also apply to our lead program, NPM-115, which is under development for chronic weight management.”
Contact: